Tradestie Institutional Equity Comparison Engine

CELC vs ZBIO โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

ZBIO Overall Edge

ZBIO Captures Institutional Edge (2โ€“1 Pillars ยท 3โ€“3 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Zenas BioPharma, Inc. Common Stock (ZBIO) driven by superior Momentum & Technical, Options & Structure while CELC counters with relative strength in Growth & Margin. Fundamentally, CELC trades at N/M Forward P/E with 0.0% operating margin (+0.0% YoY revenue) versus ZBIO at N/M Forward P/E and -2747.5% operating margin (-100.0% YoY). In options structure, CELC sits in BREAKDOWN (60th %ile IV; Dealer Gamma Walls on Pro) against ZBIO sits in CONSOLIDATION (13th %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner Tie
CELC N/M vs ZBIO N/M Fwd P/E
Growth & Margin Winner CELC
Op Margin 0.0% vs -2747.5% ยท YoY +0.0% vs -100.0%
Momentum & Technical Winner ZBIO
1Y -29.6% vs -21.7% ยท 52W Pos 7% vs 46%
Options & Structure Winner ZBIO
BREAKDOWN (60th %ile IV) vs CONSOLIDATION (13th %ile IV)
CELC NASDAQ
Celcuity Inc. Common Stock
Services-Medical Laboratories
$60.57
-5.9% 1D
Market Cap $3.1B
1M Return +7.05%
1Y Return -29.57%
Forward P/E N/M
Unified AI Score
39.7 / 100 SELL
Tech 25.0 Fund 43.0 Flow 59.0 Mom 64.0
ZBIO NASDAQ
Zenas BioPharma, Inc. Common Stock
Pharmaceutical Preparations
$27.93
-0.29% 1D
Market Cap $1.9B
1M Return +12.44%
1Y Return -21.68%
Forward P/E N/M
Unified AI Score
49.4 / 100 HOLD
Tech 44.0 Fund 53.0 Flow 69.0 Mom 50.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: CELC -29.57% ZBIO -21.68% Spread: +7.89 pp (ZBIO Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
CELC TTM Op. Margin: 0.0% ZBIO TTM Op. Margin: -2747.5%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on CELC vs ZBIO. Trailing 12-month operating profitability (CELC 0.0% vs ZBIO -2747.5%) and valuation multiples (CELC N/M vs ZBIO N/M Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: CELC (3) vs ZBIO (3)
Institutional Metric CELC ZBIO Criterion Row Winner
Market Capitalization Scale $3.1B $1.9B Larger Scale CELC
Trailing P/E Ratio Valuation N/M N/M Lower Multiple Tie
Forward P/E Ratio Valuation N/M N/M Lower Multiple Tie
Revenue Growth (YoY) Growth +0.0% -100.0% Higher Growth CELC
Operating Margin (TTM) Profitability 0.0% -2747.5% Higher Margin CELC
Net Profit Margin Profitability 0.0% 0.0% Higher Margin Tie
Return on Equity (ROE) Capital Efficiency -1192.9% -265.1% Higher ROE ZBIO
52-Week Range Position Momentum 7% ($54โ€“$151) 46% ($14โ€“$45) Stronger Trend ZBIO
Beta / 30D Volatility Risk Regime 1.28ฮฒ ยท 59% Vol 1.16ฮฒ ยท 59% Vol Lower Realized Risk Tie
Unified Institutional Score Composite Signal 39.7 / 100 (SELL) 49.4 / 100 (HOLD) Higher Composite ZBIO

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full CELC vs ZBIO Buy Guide
CELC BREAKDOWN
136d in phase ยท OBV DISTRIBUTION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 60th %ile
IV Regime Balanced (25thโ€“60th %ile)
Live CELC Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
ZBIO CONSOLIDATION
58d in phase ยท OBV ACCUMULATION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 13th %ile
IV Regime Compressed (<25th %ile)
Live ZBIO Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither CELC nor ZBIO registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.